Published in Nanotechnology on August 06, 2010
The clinical use of indocyanine green as a near-infrared fluorescent contrast agent for image-guided oncologic surgery. J Surg Oncol (2011) 3.24
Image-guided cancer surgery using near-infrared fluorescence. Nat Rev Clin Oncol (2013) 3.01
A review of indocyanine green fluorescent imaging in surgery. Int J Biomed Imaging (2012) 2.18
Nanocolloidal albumin-IRDye 800CW: a near-infrared fluorescent tracer with optimal retention in the sentinel lymph node. Eur J Nucl Med Mol Imaging (2012) 1.49
Evaluation of a radioactive and fluorescent hybrid tracer for sentinel lymph node biopsy in head and neck malignancies: prospective randomized clinical trial to compare ICG-(99m)Tc-nanocolloid hybrid tracer versus (99m)Tc-nanocolloid. Eur J Nucl Med Mol Imaging (2015) 1.42
Intraoperative imaging-guided cancer surgery: from current fluorescence molecular imaging methods to future multi-modality imaging technology. Theranostics (2014) 1.29
Feasibility of sentinel node biopsy in head and neck melanoma using a hybrid radioactive and fluorescent tracer. Ann Surg Oncol (2011) 1.25
Concomitant radio- and fluorescence-guided sentinel lymph node biopsy in squamous cell carcinoma of the oral cavity using ICG-(99m)Tc-nanocolloid. Eur J Nucl Med Mol Imaging (2012) 1.15
Clinical trial of combined radio- and fluorescence-guided sentinel lymph node biopsy in breast cancer. Br J Surg (2013) 1.14
Optical imaging as an expansion of nuclear medicine: Cerenkov-based luminescence vs fluorescence-based luminescence. Eur J Nucl Med Mol Imaging (2013) 1.09
Dual-labeling strategies for nuclear and fluorescence molecular imaging: a review and analysis. Mol Imaging Biol (2012) 0.99
Hybrid peptide dendrimers for imaging of chemokine receptor 4 (CXCR4) expression. Mol Pharm (2011) 0.90
Targeted non-covalent self-assembled nanoparticles based on human serum albumin. Biomaterials (2011) 0.88
Multimodal interventional molecular imaging of tumor margins and distant metastases by targeting αvβ3 integrin. Chembiochem (2012) 0.83
Feasibility of Real-Time Near-Infrared Fluorescence Tracer Imaging in Sentinel Node Biopsy for Oral Cavity Cancer Patients. Ann Surg Oncol (2016) 0.82
Sentinel lymph node detection by an optical method using scattered photons. Biomed Opt Express (2010) 0.81
Hybrid surgical guidance based on the integration of radionuclear and optical technologies. Br J Radiol (2016) 0.80
Dual-modality imaging with 99mTc and fluorescent indocyanine green using surface-modified silica nanoparticles for biopsy of the sentinel lymph node: an animal study. EJNMMI Res (2013) 0.79
A new optical probe for the detection of the sentinel lymph node using patent blue V dye in breast cancer: A preliminary study. Mol Clin Oncol (2012) 0.77
Sentinel lymph nodes fluorescence detection and imaging using Patent Blue V bound to human serum albumin. Biomed Opt Express (2012) 0.75
Beyond penile cancer, is there a role for sentinel node biopsy in urological malignancies? Clin Transl Imaging (2016) 0.75
Microscopic validation of macroscopic in vivo images enabled by same-slide optical and nuclear fusion. J Nucl Med (2014) 0.75
Hybrid intraoperative imaging techniques in radioguided surgery: present clinical applications and future outlook. Clin Transl Imaging (2017) 0.75
Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med (2004) 8.91
53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat Struct Mol Biol (2010) 5.59
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A (2008) 4.61
Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell (2006) 4.15
Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood (2007) 3.67
Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc Natl Acad Sci U S A (2007) 3.58
Large-scale mutagenesis in p19(ARF)- and p53-deficient mice identifies cancer genes and their collaborative networks. Cell (2008) 3.25
Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol Cell Biol (2006) 3.24
Nesprin-3, a novel outer nuclear membrane protein, associates with the cytoskeletal linker protein plectin. J Cell Biol (2005) 3.17
Single-cell dynamics of genome-nuclear lamina interactions. Cell (2013) 3.03
Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. Cancer Discov (2012) 2.74
Cholesterol sensor ORP1L contacts the ER protein VAP to control Rab7-RILP-p150 Glued and late endosome positioning. J Cell Biol (2009) 2.45
Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc Natl Acad Sci U S A (2007) 2.39
Polo-like kinase-1 is required for bipolar spindle formation but is dispensable for anaphase promoting complex/Cdc20 activation and initiation of cytokinesis. J Biol Chem (2004) 2.37
BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance. Cancer Cell (2011) 2.35
Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors. Mol Cell Biol (2004) 2.31
Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin Cancer Res (2008) 2.27
The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nat Rev Cancer (2012) 2.20
Toxicity of ligand-dependent Cre recombinases and generation of a conditional Cre deleter mouse allowing mosaic recombination in peripheral tissues. Physiol Genomics (2007) 2.15
MMTV insertional mutagenesis identifies genes, gene families and pathways involved in mammary cancer. Nat Genet (2007) 2.14
Human and mouse oligonucleotide-based array CGH. Nucleic Acids Res (2005) 2.03
Disease-associated prion protein oligomers inhibit the 26S proteasome. Mol Cell (2007) 2.01
Quantum dots with a paramagnetic coating as a bimodal molecular imaging probe. Nano Lett (2006) 1.98
A high-throughput splinkerette-PCR method for the isolation and sequencing of retroviral insertion sites. Nat Protoc (2009) 1.95
Requirements for the localization of nesprin-3 at the nuclear envelope and its interaction with plectin. J Cell Sci (2007) 1.92
Breast tomosynthesis in clinical practice: initial results. Eur Radiol (2009) 1.89
Peptide diffusion, protection, and degradation in nuclear and cytoplasmic compartments before antigen presentation by MHC class I. Immunity (2003) 1.89
Mutagenic insertion and chromosome engineering resource (MICER). Nat Genet (2004) 1.88
High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer. Cancer Res (2009) 1.82
CIP2A is associated with human breast cancer aggressivity. Clin Cancer Res (2009) 1.81
Late endosomal transport and tethering are coupled processes controlled by RILP and the cholesterol sensor ORP1L. J Cell Sci (2013) 1.79
BRD7 is a candidate tumour suppressor gene required for p53 function. Nat Cell Biol (2010) 1.76
Blood pressure influences end-stage renal disease of Cd151 knockout mice. J Clin Invest (2011) 1.75
Pulmonary function following high-dose radiotherapy of non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2003) 1.67
Spatial separation of HLA-DM/HLA-DR interactions within MIIC and phagosome-induced immune escape. Immunity (2005) 1.64
NCAM-induced focal adhesion assembly: a functional switch upon loss of E-cadherin. EMBO J (2008) 1.62
Loss of p53 partially rescues embryonic development of Palb2 knockout mice but does not foster haploinsufficiency of Palb2 in tumour suppression. J Pathol (2011) 1.61
How do real tumors become resistant to cisplatin? Cell Cycle (2008) 1.60
Integrin alpha3beta1 inhibits directional migration and wound re-epithelialization in the skin. J Cell Sci (2009) 1.60
PIP2 signaling in lipid domains: a critical re-evaluation. EMBO J (2005) 1.59
Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype. J Clin Oncol (2011) 1.59
Developmental stage-specific contribution of LGR5(+) cells to basal and luminal epithelial lineages in the postnatal mammary gland. J Pathol (2012) 1.57
A fluorescent broad-spectrum proteasome inhibitor for labeling proteasomes in vitro and in vivo. Chem Biol (2006) 1.54
The FYVE domain in Smad anchor for receptor activation (SARA) is sufficient for localization of SARA in early endosomes and regulates TGF-beta/Smad signalling. Genes Cells (2002) 1.53
Comparing the hybrid fluorescent-radioactive tracer indocyanine green-99mTc-nanocolloid with 99mTc-nanocolloid for sentinel node identification: a validation study using lymphoscintigraphy and SPECT/CT. J Nucl Med (2012) 1.53
Identification of cancer genes using a statistical framework for multiexperiment analysis of nondiscretized array CGH data. Nucleic Acids Res (2008) 1.52
Invasive fungal infection and impaired neutrophil killing in human CARD9 deficiency. Blood (2013) 1.51
Noninvasive imaging of spontaneous retinoblastoma pathway-dependent tumors in mice. Cancer Res (2002) 1.46
Bmi1 regulates stem cells and proliferation and differentiation of committed cells in mammary epithelium. Curr Biol (2008) 1.45
Accuracy of internal mammary lymph node localization using lymphoscintigraphy, sonography and CT. Radiother Oncol (2002) 1.45
Fgf10 is an oncogene activated by MMTV insertional mutagenesis in mouse mammary tumors and overexpressed in a subset of human breast carcinomas. Oncogene (2004) 1.44
BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A. Breast Cancer Res (2009) 1.44
BRCA2 acts as a RAD51 loader to facilitate telomere replication and capping. Nat Struct Mol Biol (2010) 1.44
EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer. Breast Cancer Res (2008) 1.42
Molecular imaging of tumor angiogenesis using alphavbeta3-integrin targeted multimodal quantum dots. Angiogenesis (2008) 1.37
What makes tumors multidrug resistant? Cell Cycle (2007) 1.34
A whole-genome mouse BAC microarray with 1-Mb resolution for analysis of DNA copy number changes by array comparative genomic hybridization. Genome Res (2004) 1.32
Conditional inactivation of Brca1 in the mouse ovarian surface epithelium results in an increase in preneoplastic changes. Exp Cell Res (2006) 1.31
BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival. J Exp Med (2013) 1.30
FcRn: an IgG receptor on phagocytes with a novel role in phagocytosis. Blood (2006) 1.30
Portal imaging to assess set-up errors, tumor motion and tumor shrinkage during conformal radiotherapy of non-small cell lung cancer. Radiother Oncol (2003) 1.28
Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors? Clin Cancer Res (2013) 1.28
Keratinocytes display normal proliferation, survival and differentiation in conditional beta4-integrin knockout mice. J Cell Sci (2005) 1.27
Mice expressing a mammary gland-specific R270H mutation in the p53 tumor suppressor gene mimic human breast cancer development. Cancer Res (2005) 1.26
The Rac activator Tiam1 controls efficient T-cell trafficking and route of transendothelial migration. Blood (2009) 1.25
Molecular imaging of macrophages in atherosclerotic plaques using bimodal PEG-micelles. Magn Reson Med (2007) 1.25
Feasibility of sentinel node biopsy in head and neck melanoma using a hybrid radioactive and fluorescent tracer. Ann Surg Oncol (2011) 1.25
Optimizing radiation treatment plans for lung cancer using lung perfusion information. Radiother Oncol (2002) 1.22
A novel, simplified ex vivo method for measuring water exchange performance of heat and moisture exchangers for tracheostomy application. Respir Care (2013) 1.22
Multimodal tumor-targeting peptides functionalized with both a radio- and a fluorescent label. Bioconjug Chem (2010) 1.20
Chemotherapy response of spontaneous mammary tumors is independent of the adaptive immune system. Nat Med (2012) 1.19
Factors affecting sensitivity and specificity of screening mammography and MRI in women with an inherited risk for breast cancer. Breast Cancer Res Treat (2006) 1.18
Moderate increase in Mdr1a/1b expression causes in vivo resistance to doxorubicin in a mouse model for hereditary breast cancer. Cancer Res (2009) 1.18
Additional breast lesions in patients eligible for breast-conserving therapy by MRI: impact on preoperative management and potential benefit of computerised analysis. Eur J Cancer (2005) 1.18
A high-throughput functional complementation assay for classification of BRCA1 missense variants. Cancer Discov (2013) 1.17
Rapid target gene validation in complex cancer mouse models using re-derived embryonic stem cells. EMBO Mol Med (2014) 1.17
Tracer-cocktail injections for combined pre- and intraoperative multimodal imaging of lymph nodes in a spontaneous mouse prostate tumor model. J Biomed Opt (2011) 1.16
Mammary-specific inactivation of E-cadherin and p53 impairs functional gland development and leads to pleomorphic invasive lobular carcinoma in mice. Dis Model Mech (2011) 1.16
Combinatorial SNARE complexes modulate the secretion of cytoplasmic granules in human neutrophils. J Immunol (2006) 1.16
Dual Role of alpha6beta4 integrin in epidermal tumor growth: tumor-suppressive versus tumor-promoting function. Mol Biol Cell (2007) 1.16
Further evidence for BRCA1 communication with the inactive X chromosome. Cell (2007) 1.15
Concomitant radio- and fluorescence-guided sentinel lymph node biopsy in squamous cell carcinoma of the oral cavity using ICG-(99m)Tc-nanocolloid. Eur J Nucl Med Mol Imaging (2012) 1.15
Fibroblast growth factor receptor 1-transformed mammary epithelial cells are dependent on RSK activity for growth and survival. Cancer Res (2009) 1.15
Image-guided hepatopancreatobiliary surgery using near-infrared fluorescent light. J Hepatobiliary Pancreat Sci (2012) 1.14
Annexin A5-conjugated quantum dots with a paramagnetic lipidic coating for the multimodal detection of apoptotic cells. Bioconjug Chem (2006) 1.14
Differences between first and subsequent rounds of the MRISC breast cancer screening program for women with a familial or genetic predisposition. Cancer (2006) 1.14
Cytosolic p120-catenin regulates growth of metastatic lobular carcinoma through Rock1-mediated anoikis resistance. J Clin Invest (2011) 1.13
Mouse models for BRCA1 associated tumorigenesis: from fundamental insights to preclinical utility. Cell Cycle (2008) 1.12
Modeling therapy resistance in genetically engineered mouse cancer models. Drug Resist Updat (2007) 1.12
High-throughput semiquantitative analysis of insertional mutations in heterogeneous tumors. Genome Res (2011) 1.12
Expression and regulation of the metalloproteinase ADAM-8 during human neutrophil pathophysiological activation and its catalytic activity on L-selectin shedding. J Immunol (2007) 1.11
BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study. J Clin Oncol (2010) 1.11
Optical imaging as an expansion of nuclear medicine: Cerenkov-based luminescence vs fluorescence-based luminescence. Eur J Nucl Med Mol Imaging (2013) 1.09
Telomerase deletion limits progression of p53-mutant hepatocellular carcinoma with short telomeres in chronic liver disease. Gastroenterology (2007) 1.08
Synergistic tumour suppressor activity of E-cadherin and p53 in a conditional mouse model for metastatic diffuse-type gastric cancer. Gut (2011) 1.08
Deleted in colorectal carcinoma suppresses metastasis in p53-deficient mammary tumours. Nature (2012) 1.08
Somatic structural rearrangements in genetically engineered mouse mammary tumors. Genome Biol (2010) 1.06
Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan. Cancer Res (2010) 1.06